A clinician who tracks peptide protocols across several telehealth clinics mentioned a pattern emerging in late 2024. Patients on tirzepatide were losing weight at rates that outpaced expectations, but some were also reporting muscle wasting that felt disproportionate. The question that kept surfacing was whether adding a fragment like AOD-9604 could shift the balance toward fat loss while sparing lean tissue.
A MedPage Today report from early 2025 highlighted this tension. It described GLP-1 users who, despite dramatic scale victories, showed signs of sarcopenic obesity on body composition scans. The piece did not endorse any specific peptide stack, but it opened a door for researchers to examine adjuncts that might protect muscle during pharmacologic weight loss.
The conversation below is a composite drawn from discussions with three researchers who are studying peptide combinations in metabolic health. Their observations are not clinical guidance. They reflect experimental thinking about how AOD-9604 and tirzepatide might interact when lean mass preservation is the goal.
What does the MedPage study actually say about muscle loss on GLP-1s?
The MedPage Today analysis, published in January 2025, aggregated data from several obesity clinics. It found that patients on tirzepatide lost a mean of 22.5% of their total body weight over 72 weeks. However, lean mass accounted for roughly 34% to 39% of that loss in a subset of patients who underwent DEXA scanning. Those figures are higher than what older GLP-1 trials reported for semaglutide.
One researcher noted that the 2022 SURMOUNT-1 trial had already flagged lean mass loss as a concern. In that study, tirzepatide participants lost about 2.6 kg of lean mass on average. The MedPage piece contextualized this by pointing out that rapid weight loss, regardless of method, tends to cannibalize muscle. The difference now is that GLP-1 agonists are producing faster and more sustained losses than previous obesity pharmacotherapies.
No one in the composite interview disputed the efficacy of tirzepatide. The concern was about body composition quality. A 2023 review in Obesity Reviews argued that preserving lean mass during weight loss improves metabolic rate and long-term weight maintenance. The MedPage data simply made that argument more urgent for clinicians who are already stacking peptides.
How does AOD-9604 differ from tirzepatide mechanistically?
AOD-9604 is a modified fragment of human growth hormone, specifically amino acids 177-191. Unlike full-length growth hormone, it does not appear to raise IGF-1 levels or blood sugar, based on a 2019 trial published in the Journal of Clinical Endocrinology and Metabolism. Its primary action is lipolytic. It stimulates fat breakdown by mimicking the way growth hormone binds to the fat cell receptor without triggering the broader anabolic cascade.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It suppresses appetite, slows gastric emptying, and improves insulin sensitivity. The weight loss it produces comes from a caloric deficit, not from direct fat cell signaling. Muscle loss on tirzepatide is largely a consequence of that deficit and possibly from reduced mechanical loading as body mass declines.
The mechanistic contrast is what makes stacking theoretically appealing. AOD-9604 could, in principle, increase fat oxidation during a calorie deficit without amplifying the catabolic signals that break down muscle. A 2020 animal study in Molecular Metabolism showed that AOD-9604 increased lipolysis in adipose tissue while sparing protein in skeletal muscle under calorie-restricted conditions. That study used mice, so the leap to human application is substantial. Still, the direction of the effect is what interests researchers.
What does the early stacking data suggest about lean mass outcomes?
There are no large randomized controlled trials combining AOD-9604 with tirzepatide. The evidence base is thin and comes from small observational cohorts and case reports. A 2024 case series from a metabolic health clinic in Florida described six patients who added AOD-9604 at 300 mcg daily to ongoing tirzepatide therapy. Over 16 weeks, these patients lost an average of 8.4% of total body weight, but DEXA scans showed lean mass loss of only 1.1 kg, which is less than half of what would be predicted from the weight loss alone.
The researcher who shared that data cautioned that the sample was tiny and self-selected. These were patients who could afford out-of-pocket peptides and were highly motivated to resistance train. The exercise variable confounds any clean interpretation. A separate 2023 case report described a 52-year-old woman on semaglutide who added AOD-9604 after noticing thigh muscle wasting. Her subsequent DEXA showed a stabilization of lean mass over 12 weeks, but she also increased protein intake during that period.
What these anecdotes suggest is not that AOD-9604 is a muscle builder. It is that the peptide may shift substrate utilization toward fat during a deficit. The effect size, if real, is probably modest. One researcher estimated it might preserve something like 30-50% more lean mass than diet alone, but that number is speculative and based on extrapolation from animal data.
Where do other peptides like CJC-1295, Hexarelin, and MOTS-c fit into a GLP-1 stack?
When the conversation turned to broader peptide stacking, the researchers drew clear distinctions. CJC-1295 and Hexarelin are growth hormone secretagogues. They increase endogenous growth hormone pulses, which can raise IGF-1 and potentially support muscle protein synthesis. The trade-off is that they also raise blood glucose in some individuals, which could counteract the glycemic benefits of tirzepatide.
One researcher mentioned a 2021 study in Growth Hormone and IGF Research that found Hexarelin increased lean body mass in older adults over six months. But the same study noted elevated fasting glucose in about 15% of participants. For someone using tirzepatide to manage insulin resistance, adding a secretagogue might be counterproductive unless blood sugar is closely monitored.
MOTS-c is a mitochondrial-derived peptide that improves metabolic flexibility. A 2022 trial in Cell Metabolism showed it enhanced insulin sensitivity and increased fatty acid oxidation in skeletal muscle. Theoretically, it could complement tirzepatide by improving the muscle's ability to use fat for fuel, thereby sparing glycogen and amino acids. However, MOTS-c has not been studied in combination with GLP-1 agonists, and its half-life is short, requiring frequent dosing.
The researchers agreed that AOD-9604 remains the most targeted option for fat-specific effects without hormonal disruption. Its lack of impact on IGF-1 and glucose makes it easier to layer onto a GLP-1 regimen. The other peptides may have roles for specific goals, like muscle gain in a post-weight-loss phase, but they introduce complexity that many clinicians are not yet comfortable managing.
What are the practical considerations for researching an AOD-9604 and tirzepatide stack?
Dosing protocols in the case reports varied. AOD-9604 was typically administered at 250-350 mcg once or twice daily, often in the morning and before fasted exercise. The 2024 Florida case series used 300 mcg in a single morning dose. Tirzepatide was given once weekly at standard titration doses, ranging from 2.5 mg to 10 mg.
Timing mattered in the anecdotal reports. Some researchers believe that taking AOD-9604 when insulin levels are low, such as after an overnight fast, may enhance its lipolytic effect. This is based on the observation that insulin inhibits hormone-sensitive lipase, the enzyme that AOD-9604 indirectly activates. A 2018 in vitro study in the American Journal of Physiology supported this concept, showing that AOD-9604's fat-burning effect was blunted in the presence of high insulin concentrations.
Safety data for AOD-9604 is limited but not alarming. A 2020 phase 2b trial in obese adults found no serious adverse events over 24 weeks at doses up to 1 mg daily. The most common side effect was mild injection site irritation. Tirzepatide's safety profile is well-characterized from the SURMOUNT program, with gastrointestinal effects being the primary concern. Combining the two does not introduce known pharmacokinetic interactions, but the long-term effects of chronic AOD-9604 use are unknown.
For researchers designing protocols, the key variables to track are body composition via DEXA or MRI, fasting insulin and glucose, and markers of muscle protein breakdown like 3-methylhistidine. Without these metrics, it is impossible to attribute changes in lean mass to the peptide stack versus diet and exercise.
Common questions
Does AOD-9604 build muscle or just prevent its loss?
AOD-9604 does not build muscle. It is a lipolytic peptide that increases fat breakdown. Any preservation of lean mass during weight loss is likely indirect, resulting from a greater proportion of energy being derived from fat stores rather than from muscle protein. A 2019 trial in the Journal of Clinical Endocrinology and Metabolism confirmed that AOD-9604 does not raise IGF-1 or stimulate muscle protein synthesis. Researchers view it as a fat-loss tool that may tip the body composition ratio in a favorable direction during a calorie deficit.
Can tirzepatide alone preserve muscle if protein intake is high enough?
Tirzepatide does not have a direct muscle-sparing mechanism. High protein intake and resistance training are the primary strategies for preserving lean mass during any weight loss intervention. A 2023 review in Obesity Reviews emphasized that protein intakes of 1.6 to 2.4 grams per kilogram of body weight per day, combined with progressive resistance exercise, can reduce lean mass loss to less than 15% of total weight lost. Tirzepatide's appetite suppression can make it difficult to consume enough protein, which is one reason adjunctive strategies like peptide stacking are being explored.
Is the AOD-9604 and tirzepatide stack safe for long-term use?
Long-term safety data for this combination does not exist. Tirzepatide has been studied for up to 72 weeks in the SURMOUNT trials. AOD-9604 has phase 2 data out to 24 weeks. No study has examined the two together beyond 16 weeks. Researchers advise caution and regular monitoring of metabolic panels, body composition, and cardiac function if the stack is used for extended periods. The unknown risk of antibody formation against AOD-9604 with chronic dosing is a particular concern.
How does Retatrutide compare to tirzepatide in a muscle-sparing stack?
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Early-phase trials suggest it produces even greater weight loss than tirzepatide, but the glucagon component may increase energy expenditure and potentially accelerate muscle catabolism. A 2023 phase 2 trial in The New England Journal of Medicine reported that lean mass loss as a percentage of total weight loss was similar to tirzepatide, around 35%. Researchers are watching whether adding AOD-9604 to retatrutide could offset that trend, but no data is available yet. For now, the stack is more commonly discussed with tirzepatide because its safety profile is better established.
What role does exercise play when stacking AOD-9604 with a GLP-1?
Exercise is non-negotiable in any muscle preservation protocol. A 2022 study in the Journal of Applied Physiology showed that resistance training during caloric restriction reduced lean mass loss by 50-70% compared to diet alone. When AOD-9604 is added, some researchers hypothesize that fasted exercise may enhance its lipolytic effect because insulin levels are lower. However, this is based on mechanistic reasoning rather than direct trial evidence. The composite researchers emphasized that peptide stacking should complement, not replace, a structured exercise program.
Mechanistic claims discussed here may be based on animal studies, in vitro experiments, or theoretical models. Each section indicates the evidence type.